Glioblastoma Multiforme Clinical Trials

37 studies are recruiting for glioblastoma multiforme in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Study of Pembrolizumab and M032 (NSC 733972)

   This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II portion using a Recommended Phase 2 Dose (RP2D) of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05084430 on ClinicalTrials.gov

2. Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

   The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Johns Hopkins Medical Institution, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05083754 on ClinicalTrials.gov

3. Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

   This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA appr…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Stony Brook University Hospital, Stony Brook, New York

   Run by

   Stony Brook University

   See if you can join NCT05423210 on ClinicalTrials.gov

4. Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

   The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Run by

   Henry Ford Health System

   See if you can join NCT05686798 on ClinicalTrials.gov

5. Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

   This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Jackson Memorial Hospital, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT05956821 on ClinicalTrials.gov

6. Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

   The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California at Los Angeles, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT06059690 on ClinicalTrials.gov

7. Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

   The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, an…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Chirag G. Patil

   See if you can join NCT04977375 on ClinicalTrials.gov

8. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

   To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

   Locations

   35 in total

   Run by

   Apollomics Inc.

   See if you can join NCT03175224 on ClinicalTrials.gov

9. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

   The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   8 in total

   Run by

   Orbus Therapeutics, Inc.

   See if you can join NCT05879367 on ClinicalTrials.gov

10. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

    Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06283927 on ClinicalTrials.gov

11. The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

    There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internation…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146725 on ClinicalTrials.gov

12. The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

    There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This stu…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146738 on ClinicalTrials.gov